Studies from Hainz et al. [14,15,16] using the pannexin-1 antagonist probenecid showed protective effects on MS murine models, such as preventing and arresting the progression of clinical symptoms in an EAE mouse model and diminishing demyelination in the cuprizone mouse model of demyelination/remyelination. Here, PANX1 is linked to myeloid sarcoma.